Did you mean?
Search Results - Showing 0 - 12 Of 33
_venetoclax-plus-obinutuzumab-improves-pfs-and-mrd-negativity-in-patients-with-previously-untreated-cll-and-comorbidities.jpg "Dr Kirsten Fischer presents results at the 2019 European Hematology Association (EHA) Annual Meeting from the multinational, open-label, phase 3 CLL14 trial.nnFixed-duration venetoclax plus obinutuzumab induced deep, high, and long lasting MRD-negativity rates in previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities, with this translating into improved progression-free survival (PFS).")
⏲ 6 min 45 sec ✓ 14-Jun-2019
_reveng-venetoclax-and-obinutuzumab-in-cll.jpg "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 1 minute 👁 366
_venetoclax-and-obinutuzumab-for-cll.jpg "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 48 seconds 👁 133
_cll14-venetoclax-plus-obinutuzumab-in-untreated-cll.jpg "Dr Othman Al-Sawaf speaks to ecancer about the four-year follow-up of the CLL14 trial looking at venetoclax and obinutuzumab in untreated chronic lymphocyte leukaemia. nnDr Al Sawaf explains that venetoclax plus obinutuzumab has been established as a fixed-duration treatment regimen for patients with chronic lymphocytic leukaemia. In the CLL14 trial, the long-term efficacy after treatment cessation of the combination of venetoclax plus obinutuzumab with chlorambucil plus obinutuzumab was compare")
⏲ 3 min 11 sec ✓ 11-Jun-2021
_six-year-update-from-cll14-fixed-duration-venetoclax-obinutuzumab-for-previously-untreated-cll.jpg "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 1 minute 43 seconds 👁 88
_6-year-results-of-cll14-venetoclax-obinutuzumab-for-previously-untreated-cll.jpg "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 5 minutes 59 seconds 👁 828
_kirsten-fischer-new-fixed-duration-venetoclax-plus-obinutuzumab-in-previously-untreated-patients-with-cll.jpg "Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL) and coexisting comorbidities (abstract S149)nPresenter: Dr Kirsten Fischer – Germany - Recorded @ EHA Press Briefing, Friday, June 14, 2019 @ RAI in AmsterdamnMore info @ https://oncoletter.ch")
⏲ 6 min 66 sec ✓ 14-Jun-2019
_majic-venetoclax-with-acalabrutinib-or-obinutuzumab-in-cll.jpg "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 1 minute 9 seconds 👁 291
_venetoclax-obinutuzumab-impact-on-cll-management.jpg "OncLiveTV")
⏲ 7 minutes 29 seconds 👁 2.4K
_amy-pierre-anp-bc-on-cll-in-older-patients-the-alliance-trial-on-ibrutinib-obinutuzumab-and-venetoclax.jpg "Amy Pierre, ANP-BC, on CLL in Older Patients: The Alliance Trial on Ibrutinib, Obinutuzumab, and Venetoclax from obinutuzumab and venetoclax in cll")
⏲ 1 min 41 sec ✓ 09-Dec-2019
_cll14-venetoclax-plus-obinutuzumab-for-cll.jpg "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 5 minutes 54 seconds 👁 476
_cll-venetoclax-in-combination-with-obinutuzumab.jpg "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 1 minute 35 seconds 👁 78
Related Searches
Search Videos
Recent Searches
_venetoclax-plus-obinutuzumab-improves-pfs-and-mrd-negativity-in-patients-with-previously-untreated-cll-and-comorbidities.webp "Dr Kirsten Fischer presents results at the 2019 European Hematology Association (EHA) Annual Meeting from the multinational, open-label, phase 3 CLL14 trial.nnFixed-duration venetoclax plus obinutuzumab induced deep, high, and long lasting MRD-negativity rates in previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities, with this translating into improved progression-free survival (PFS).")
_reveng-venetoclax-and-obinutuzumab-in-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_venetoclax-and-obinutuzumab-for-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_cll14-venetoclax-plus-obinutuzumab-in-untreated-cll.webp "Dr Othman Al-Sawaf speaks to ecancer about the four-year follow-up of the CLL14 trial looking at venetoclax and obinutuzumab in untreated chronic lymphocyte leukaemia. nnDr Al Sawaf explains that venetoclax plus obinutuzumab has been established as a fixed-duration treatment regimen for patients with chronic lymphocytic leukaemia. In the CLL14 trial, the long-term efficacy after treatment cessation of the combination of venetoclax plus obinutuzumab with chlorambucil plus obinutuzumab was compare")
_six-year-update-from-cll14-fixed-duration-venetoclax-obinutuzumab-for-previously-untreated-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_6-year-results-of-cll14-venetoclax-obinutuzumab-for-previously-untreated-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_kirsten-fischer-new-fixed-duration-venetoclax-plus-obinutuzumab-in-previously-untreated-patients-with-cll.webp "Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL) and coexisting comorbidities (abstract S149)nPresenter: Dr Kirsten Fischer – Germany - Recorded @ EHA Press Briefing, Friday, June 14, 2019 @ RAI in AmsterdamnMore info @ https://oncoletter.ch")
_majic-venetoclax-with-acalabrutinib-or-obinutuzumab-in-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_venetoclax-obinutuzumab-impact-on-cll-management.webp "OncLiveTV")
_amy-pierre-anp-bc-on-cll-in-older-patients-the-alliance-trial-on-ibrutinib-obinutuzumab-and-venetoclax.webp "Amy Pierre, ANP-BC, on CLL in Older Patients: The Alliance Trial on Ibrutinib, Obinutuzumab, and Venetoclax from obinutuzumab and venetoclax in cll")
_cll14-venetoclax-plus-obinutuzumab-for-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_cll-venetoclax-in-combination-with-obinutuzumab.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
![[+]](/images/menu.gif){kind=small}